Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414880 | 0.93 | MAOB (0.38) | MTNR1AMTNR1BGAAREN | |
| SCHEMBL3072274 | 0.91 | CNR1 (0.34) | MTNR1AMTNR1BGAANPC1APOBEC3A | |
| SCHEMBL3071552 | 0.87 | MTNR1A (0.38) | MTNR1AMTNR1BGAANPC1APOBEC3A | |
| SCHEMBL3059850 | 0.87 | MTNR1A (0.42) | MTNR1AMTNR1BGAAREN | |
| SCHEMBL3072453 | 0.85 | REN (0.49) | MTNR1AMTNR1BNPC1APOBEC3ARAB9A | |
| SCHEMBL3067279 | 0.85 | YAP1 (0.42) | — | |
| SCHEMBL3070956 | 0.83 | MTNR1B (0.44) | MTNR1AMTNR1BNPC1APOBEC3ARAB9A | |
| SCHEMBL3081602 | 0.81 | MAPT (0.40) | — | |
| SCHEMBL3413716 | 0.81 | ACACB (0.43) | — | |
| SCHEMBL3418040 | 0.81 | REN (0.39) | MTNR1AMTNR1BREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | MTNR1A 2695/4885MTNR1B 1389/4885GAA 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.